KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclit…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of ...
Frontiers

Mirror Mechanisms: Neurodevelopmental Pathways Reflected in Alzheimer’s Disease

One of the most important and least resolved questions in Alzheimer’s disease and related dementias (ADRDs) is why brain-damaging pathology emerges in later ...